Monita
Technology
Enterprise
Monita
Technology
Enterprise
Amo la tecnologia medica
MTE International -Genomadix
Campobasso, Italy, 10 of June 2024. MTE International (www.mte-intl.com) is proud to announce a commercial partnership with Genomadix (www.genomadix.com) for the distribution in Italy and other EU Countries of The Genomadix CYP2C19 Test. 1-hour CYP2C19 Genotyping can help guide DAPT to reduce the risk of recurrent stroke in minor stroke/high risk TIA.
Genomadix has developed the Cube, the world’s first real-time PCR point of need platform for precision medicine testing and other applications.
-
Genomadix produces molecular tests for precision medicine genotyping and environmental/water safety testing.
-
Genomadix commercializes the Cube CYP2C19 Genotyping Test, the world’s fastest and easiest FDA-cleared CYP2C19 genotyping test, which can be used to support dual antiplatelet therapy decisions for stroke and cardiology patients.
MTE Internazionale -
Biosensori internazionali
Campobasso, Italia, 18 dicembre 2023. MTE International (www.mte-intl.com) è orgogliosa di annunciare una partnership commerciale con Biosensors International (https://www.biosensors.com/intl/allegra-overview) per la distribuzione di tecnologie innovative in cardiologia interventistica ( sistema TAVI ) in alcune regioni italiane.
Da oltre 25 anni, il Biosensors International Group ("Biosensors") progetta, produce e commercializza dispositivi medici innovativi utilizzati durante gli interventi chirurgici cardiaci e i trattamenti di terapia intensiva.
MTE International - Blue Medical
una società del gruppo Translumina
Campobasso, Italia, 16 agosto 2023. MTE International (www.mte-intl.com) è orgogliosa di annunciare una partnership commerciale con BlueMedical, una società del gruppo Translumina (https://www.wellinq.com/fabrication/protege-nc/) per la distribuzione di tecnologie innovative in cardiologia interventistica in alcune regioni italiane.
BlueMedical, fondata nel 2013, produce cateteri a palloncino, inclusi palloncini rivestiti di farmaco (DCB) e altri palloncini speciali per interventi coronarici complessi. BlueMedical ha sviluppato i cateteri Protégé NC e Protégé DCB per superare al meglio le attuali tecnologie DCB e per garantire elevati livelli di sicurezza ed efficacia. La tecnologia Protégé evita qualsiasi perdita di farmaco durante l'avanzamento del dispositivo verso la lesione, contribuendo a rilasciare un'elevata concentrazione di farmaco nel sito bersaglio.
MTE International - Abbott Medical
Campobasso, Italia, 1° gennaio 2024. MTE International (www.mte-intl.com) è orgogliosa di annunciare una partnership commerciale con Abbott Medical (www.abbott.com) per la distribuzione del sistema Diamondback 360 per l'aterectomia orbitaria coronarica nella regione Molise.
MTE International - McHealth
Campobasso, Italy, August 2022. MTE International (www.mte-intl.com) is proud to announce a commercial partnership with McHealth Srl for the distribution of interventional cardiology breakthrough technologies in Molise Region.
MC Health is the national distributor for OrbusNeich (www.orbusneich.com) of their range of innovative devices including an extensive portfolio of high-performance balloons (Sapphire family, Jade Family), speciality catheters (Scoreflex), microcatheters (Teleport and Teleport Control).
MTE International - MeMed
Campobasso, Italy, 1st of December 2021. MTE International (www.mte-intl.com) is proud to announce a commercial partnership with MeMed (www.memed.com) for the distribution in Italy of a breakthrough innovative technology: MeMed Covid-19 Severity™ on MeMed Key®.
MeMed COVID-19 Severity is a pioneering host-response technology that decodes signals of the immune system to accurately determine whether SARS-Cov-2 patients are likely to have a severe outcome. It does so by measuring multiple proteins from a serum sample and applying a machine-learning algorithm to stratify a patient's risk to experience a severe outcomes.
The test runs in 15 minutes on the company’s point-of-need platform, MeMed Key.®. The test aims to help physicians identify who may benefit from escalated care, and who can be safely discharged from hospital and to self-isolate at home. MeMed COVID-19 Severity™ has a CE Mark in Europe.
MTE International - Translumina GmbH
Campobasso, Italy, 30th of April 2021. MTE International (www.mte-intl.com) is proud to announce a commercial partnership with Translumina GmbH (www.translumina.com) for the distribution of interventional cardiology breakthrough technologies in Abruzzo, Marche, Molise & Umbria regions.
VIVO ISAR Stent: an innovative technology which eliminates the use of Polymer by using Dual Drug Technology: Sirolimus and Probucol.
10 years follow up clinical data of safety and efficacy in 3002 patients is published in Journal of American College of Cardiology. At 10 year clinical outcomes of stent thrombosis from RCTs in Patients with Coronary Artery Disease, VIVO ISAR demonstrated lower definite/ probable stent thrombosis rate than Xience (ISAR TEST-4) and Resolute.
Yukon Drug Eluting Stent is recommended by the latest European Society of Cardiology (ESC) guidelines for myocardial revascularization.
"Ten-Year Clinical Outcomes From a Trial of Three Limus-Eluting Stents With Different Polymer Coatings in Patients With Coronary Artery Disease Results From the ISAR-TEST 4 Randomized Trial"
Circulation -2018.
In this unique long term analysis at 10 years, Yukon has shown the lowest rate of Definite/ Probable Stent Thrombosis with a significant risk reduction than Cypher (50%) and numerically lower TLR rates as compared to Xience (29%) while maintaining the similar efficacy.
MTE International - Dianosic
Campobasso, Italy, 7th of April 2021. MTE International (www.mte-intl.com) is proud to announce a commercial partnership with dianosic (www.dianosic.com) for the distribution of CAVI-T , a Breakthrough innovative technology for ENT diseases, for the entire Italian territory.
Dianosic works with healthcare professionals to provide life-changing solutions for patients in the management of intranasal bleeding (epistaxis) and chronic sinusitis. This start-up is part of the selection of Challenges "100 start-ups to invest in 2021.
Intranasal bleeding is very common, costly and has a negative impact on patient’s quality of life. This is particularly noticeable in Chronic cases, epistaxis also greatly impacts care givers quality of life. The “disease” incidence is increasing due to population ageing and exacerbated by the growth of the number of patients suffering from cardiovascular diseases and being treated with anticoagulants.